Nocturnal non invasive ventilation in normocapnic cystic fibrosis patients: a pilot study.
Journal
Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064
Informations de publication
Date de publication:
12 05 2021
12 05 2021
Historique:
received:
22
01
2021
accepted:
12
02
2021
entrez:
14
5
2021
pubmed:
15
5
2021
medline:
29
6
2021
Statut:
epublish
Résumé
In patients with cystic fibrosis (CF) non-invasive ventilation (NIV) improves lung mechanics and gas exchange, and decreases the work of breathing. Domiciliary NIV is mainly used in hypercapnic patients with severe disease, because it counteracts the progression of lung functional impairment and it is often used as a useful "bridge" to lung transplantation. However, to date, there are no standardized criteria to indicate the effect of a precocious starting of NIV in patients with functional ventilation inhomogeneity without hypercapnia. In this pilot study we assessed whether an early NIV treatment might influence functional and clinical outcomes in CF patients. Six normocapnic CF patients were treated for one year with NIV. At baseline and after 1 year of NIV treatment, arterial gas analysis, spirometry, MBW to derive LCI, nocturnal cardio-respiratory polygraphy (PG), and Pittsburgh Sleep Quality Index (PSQI) were perfomed in all enrolled patients. After one year, despite spirometric and LCI values remain statistically not modified, the number of infectious exacerbations was reduced by 50%. These results suggest that nocturnal NIV improves clinical conditions of stable CF patients. Finally, we suggest that this procedure can be useful to counteract the progression of lung disease even in normocapnic patients.
Sections du résumé
BACKGROUND AND AIM
In patients with cystic fibrosis (CF) non-invasive ventilation (NIV) improves lung mechanics and gas exchange, and decreases the work of breathing. Domiciliary NIV is mainly used in hypercapnic patients with severe disease, because it counteracts the progression of lung functional impairment and it is often used as a useful "bridge" to lung transplantation. However, to date, there are no standardized criteria to indicate the effect of a precocious starting of NIV in patients with functional ventilation inhomogeneity without hypercapnia. In this pilot study we assessed whether an early NIV treatment might influence functional and clinical outcomes in CF patients.
METHODS
Six normocapnic CF patients were treated for one year with NIV. At baseline and after 1 year of NIV treatment, arterial gas analysis, spirometry, MBW to derive LCI, nocturnal cardio-respiratory polygraphy (PG), and Pittsburgh Sleep Quality Index (PSQI) were perfomed in all enrolled patients.
RESULTS
After one year, despite spirometric and LCI values remain statistically not modified, the number of infectious exacerbations was reduced by 50%.
CONCLUSIONS
These results suggest that nocturnal NIV improves clinical conditions of stable CF patients. Finally, we suggest that this procedure can be useful to counteract the progression of lung disease even in normocapnic patients.
Identifiants
pubmed: 33988138
doi: 10.23750/abm.v92i2.11261
pmc: PMC8182613
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2021164Références
Eur Respir J. 2013 Mar;41(3):507-22
pubmed: 23397305
Psychiatry Res. 1989 May;28(2):193-213
pubmed: 2748771
N Engl J Med. 1994 Sep 8;331(10):637-42
pubmed: 7503821
Eur Respir J. 2002 Feb;19(2):310-3
pubmed: 11866011
J Cyst Fibros. 2012 May;11(3):187-92
pubmed: 22177738
ERJ Open Res. 2018 Feb 16;4(1):
pubmed: 29707562
J Clin Sleep Med. 2017 Mar 15;13(3):479-504
pubmed: 28162150
Cochrane Database Syst Rev. 2017 Feb 20;2:CD002769
pubmed: 28218802
Respir Med. 1998 Oct;92(10):1215-22
pubmed: 9926152
Thorax. 2018 May;73(5):451-458
pubmed: 29449440
Int J Chron Obstruct Pulmon Dis. 2017 Jul 28;12:2197-2205
pubmed: 28814848
Thorax. 2011 Jun;66(6):481-8
pubmed: 21422040
J Pediatr. 2017 Feb;181S:S4-S15.e1
pubmed: 28129811
BMJ Open. 2015 May 19;5(5):e007418
pubmed: 25991453
Am J Respir Crit Care Med. 2001 Jan;163(1):129-34
pubmed: 11208637
Respir Res. 2009 Nov 12;10:106
pubmed: 19909502
Respir Med. 2020 Apr;164:105906
pubmed: 32217291
J Cyst Fibros. 2016 Sep;15(5):583-6
pubmed: 26778616
J Breath Res. 2016 Aug 05;10(3):035001
pubmed: 27491525
Paediatr Drugs. 2019 Aug;21(4):215-237
pubmed: 31325115
Allergy Asthma Proc. 2017 May 1;38(3):197-203
pubmed: 28441990
Chest. 2011 Jul;140(1):178-185
pubmed: 21148242
Physiother Theory Pract. 2018 Apr;34(4):264-275
pubmed: 29111843
J Cyst Fibros. 2019 Sep;18(5):665-670
pubmed: 30503032
J Biol Regul Homeost Agents. 2015 Apr-Jun;29(2 Suppl 1):47-54
pubmed: 26634587
Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88
pubmed: 31613151
J Breath Res. 2018 Feb 20;12(2):026010
pubmed: 29146889
Thorax. 2008 Feb;63(2):129-34
pubmed: 17675316
Respiration. 2008;76(2):168-74
pubmed: 17989500
Paediatr Respir Rev. 2015 Oct;16 Suppl 1:15-8
pubmed: 26420586